{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:15:13Z","timestamp":1788606913349,"version":"build-2803163510"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11402-5","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:58:52Z","timestamp":1769068732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Breaking resistance: strategies for novel antibacterial therapeutic interventions"],"prefix":"10.1007","volume":"53","author":[{"given":"Sayani","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh Pratap Singh","family":"Rathour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokul. G.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3410-4855","authenticated-orcid":false,"given":"Nidhi","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"11402_CR1","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.apjtb.2017.01.019","volume":"7","author":"HA Khan","year":"2017","unstructured":"Khan HA, Baig FK, Mehboob R (2017) Nosocomial infections: epidemiology, prevention, control and surveillance. Asian Pac J Trop Biomed 7:478\u2013482. https:\/\/doi.org\/10.1016\/j.apjtb.2017.01.019","journal-title":"Asian Pac J Trop Biomed"},{"key":"11402_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/2475067","volume":"2016","author":"S Santajit","year":"2016","unstructured":"Santajit S, Indrawattana N (2016) Mechanisms of antimicrobial resistance in pasteurellaceae. PBioMed Res Int 2016:1\u20138","journal-title":"PBioMed Res Int"},{"key":"11402_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00203-023-03455-6","volume":"205","author":"FN Idris","year":"2023","unstructured":"Idris FN, Nadzir MM (2023) Multi-drug resistant ESKAPE pathogens and the uses of plants as their antimicrobial agents. Arch Microbiol 205:1\u201315. https:\/\/doi.org\/10.1007\/s00203-023-03455-6","journal-title":"Arch Microbiol"},{"key":"11402_CR4","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/IDR.S306688","volume":"14","author":"R Pandey","year":"2021","unstructured":"Pandey R, Mishra SK, Shrestha A (2021) Characterisation of eskape pathogens with special reference to multidrug resistance and biofilm production in a nepalese hospital. Infect Drug Resist 14:2201\u20132212. https:\/\/doi.org\/10.2147\/IDR.S306688","journal-title":"Infect Drug Resist"},{"key":"11402_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijheh.2022.114006","volume":"244","author":"J Denissen","year":"2022","unstructured":"Denissen J, Reyneke B, Waso-Reyneke M et al (2022) Prevalence of ESKAPE pathogens in the environment: antibiotic resistance status, community-acquired infection and risk to human health. Int J Hyg Environ Health 244:114006. https:\/\/doi.org\/10.1016\/j.ijheh.2022.114006","journal-title":"Int J Hyg Environ Health"},{"key":"11402_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2023.1159798","volume":"13","author":"P Venkateswaran","year":"2023","unstructured":"Venkateswaran P, Vasudevan S, David H et al (2023) Revisiting ESKAPE pathogens: virulence, resistance, and combating strategies focusing on quorum sensing. Front Cell Infect Microbiol 13:1\u201330. https:\/\/doi.org\/10.3389\/fcimb.2023.1159798","journal-title":"Front Cell Infect Microbiol"},{"key":"11402_CR7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2006.03.011","volume":"119","author":"FC Tenover","year":"2006","unstructured":"Tenover FC (2006) Mechanisms of antimicrobial resistance in bacteria. Am J Med 119:S3\u2013S10. https:\/\/doi.org\/10.1016\/j.amjmed.2006.03.011","journal-title":"Am J Med"},{"key":"11402_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111615","volume":"16","author":"G Muteeb","year":"2023","unstructured":"Muteeb G, Rehman MT, Shahwan M, Aatif M (2023) Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review. Pharmaceuticals 16:1615. https:\/\/doi.org\/10.3390\/ph16111615","journal-title":"Pharmaceuticals"},{"key":"11402_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","volume":"37","author":"Z Pang","year":"2019","unstructured":"Pang Z, Raudonis R, Glick BR et al (2019) Antibiotic resistance in pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 37:177\u2013192. https:\/\/doi.org\/10.1016\/j.biotechadv.2018.11.013","journal-title":"Biotechnol Adv"},{"key":"11402_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2470","volume":"4","author":"W Li","year":"2013","unstructured":"Li W, Atkinson GC, Thakor NS et al (2013) Mechanism of tetracycline resistance by ribosomal protection protein Tet(O). Nat Commun 4:1477. https:\/\/doi.org\/10.1038\/ncomms2470","journal-title":"Nat Commun"},{"key":"11402_CR11","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S333433","volume":"14","author":"MC Li","year":"2021","unstructured":"Li MC, Lu J, Lu Y et al (2021) rpoB mutations and effects on rifampin resistance in Mycobacterium tuberculosis. Infect Drug Resist 14:4119. https:\/\/doi.org\/10.2147\/IDR.S333433","journal-title":"Infect Drug Resist"},{"key":"11402_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1574-6976.2007.00095.x","volume":"32","author":"A Zapun","year":"2008","unstructured":"Zapun A, Contreras-Martel C, Vernet T (2008) Penicillin-binding proteins and \u03b2-lactam resistance. FEMS Microbiol Rev 32:361\u2013385. https:\/\/doi.org\/10.1111\/j.1574-6976.2007.00095.x","journal-title":"FEMS Microbiol Rev"},{"key":"11402_CR13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/antibiotics14080778","volume":"14","author":"F Rouvier","year":"2025","unstructured":"Rouvier F, Brunel J-M, Pag\u00e8s J-M, Vergalli J (2025) Efflux-mediated resistance in enterobacteriaceae: recent advances and ongoing challenges to inhibit bacterial efflux pumps. Antibiotics (Basel) 14:778. https:\/\/doi.org\/10.3390\/antibiotics14080778","journal-title":"Antibiotics (Basel)"},{"key":"11402_CR14","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1021\/acsinfecdis.4c00091","volume":"10","author":"M Duffey","year":"2024","unstructured":"Duffey M, Jumde RP, da Costa RMA et al (2024) Extending the potency and lifespan of antibiotics: inhibitors of gram-negative bacterial efflux pumps. ACS Infect Dis 10:1458\u20131482. https:\/\/doi.org\/10.1021\/acsinfecdis.4c00091","journal-title":"ACS Infect Dis"},{"key":"11402_CR15","first-page":"22","volume":"95","author":"PA Lambert","year":"2002","unstructured":"Lambert PA (2002) Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J Royal Soc Med, Suppl 95:22\u201326","journal-title":"J Royal Soc Med, Suppl"},{"key":"11402_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/mic.0.001333","volume":"169","author":"A Gaurav","year":"2023","unstructured":"Gaurav A, Bakht P, Saini M et al (2023) Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors. Microbiology (Reading) 169:1\u201313. https:\/\/doi.org\/10.1099\/mic.0.001333","journal-title":"Microbiology (Reading)"},{"key":"11402_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2023.1305294","volume":"14","author":"EM Halawa","year":"2023","unstructured":"Halawa EM, Fadel M, Al-Rabia MW et al (2023) Antibiotic action and resistance: updated review of mechanisms, spread, influencing factors, and alternative approaches for combating resistance. Front Pharmacol 14:1\u201317. https:\/\/doi.org\/10.3389\/fphar.2023.1305294","journal-title":"Front Pharmacol"},{"key":"11402_CR18","doi-asserted-by":"publisher","first-page":"D574","DOI":"10.1093\/nar\/gkw1009","volume":"45","author":"SM Lakin","year":"2017","unstructured":"Lakin SM, Dean C, Noyes NR et al (2017) MEGARes: an antimicrobial resistance database for high throughput sequencing. Nucleic Acids Res 45:D574\u2013D580. https:\/\/doi.org\/10.1093\/nar\/gkw1009","journal-title":"Nucleic Acids Res"},{"key":"11402_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-021-04045-6","volume":"599","author":"MJ Mitcheltree","year":"2021","unstructured":"Mitcheltree MJ, Pisipati A, Syroegin EA et al (2021) A synthetic antibiotic class overcoming bacterial multidrug resistance. Nature 599:507\u2013512. https:\/\/doi.org\/10.1038\/s41586-021-04045-6","journal-title":"Nature"},{"key":"11402_CR20","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/cid\/ciz710","volume":"70","author":"TM File","year":"2020","unstructured":"File TM, Goldberg L, Das A et al (2020) Erratum: Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial. Clinical Infectious Dis 70:2459. https:\/\/doi.org\/10.1093\/cid\/ciz710","journal-title":"Clinical Infectious Dis"},{"key":"11402_CR21","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1021\/jacs.9b01693","volume":"141","author":"T Matsushita","year":"2019","unstructured":"Matsushita T, Sati GC, Kondasinghe N et al (2019) Design, multigram synthesis, and in vitro and in vivo evaluation of propylamycin: a semisynthetic 4,5-deoxystreptamine class aminoglycoside for the treatment of drug-resistant enterobacteriaceae and other gram-negative pathogens. J Am Chem Soc 141:5051\u20135061. https:\/\/doi.org\/10.1021\/jacs.9b01693","journal-title":"J Am Chem Soc"},{"key":"11402_CR22","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1021\/acsinfecdis.0c00223","volume":"6","author":"J Peek","year":"2020","unstructured":"Peek J, Xu J, Wang H et al (2020) A semisynthetic kanglemycin shows in vivo efficacy against high-burden rifampicin resistant pathogens. ACS Infect Dis 6:2431\u20132440. https:\/\/doi.org\/10.1021\/acsinfecdis.0c00223","journal-title":"ACS Infect Dis"},{"key":"11402_CR23","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1021\/acschembio.0c00091","volume":"15","author":"P Sarkar","year":"2020","unstructured":"Sarkar P, Samaddar S, Ammanathan V et al (2020) Vancomycin derivative inactivates carbapenem-resistant acinetobacter baumannii and induces autophagy. ACS Chem Biol 15:884\u2013889. https:\/\/doi.org\/10.1021\/acschembio.0c00091","journal-title":"ACS Chem Biol"},{"key":"11402_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11040425","author":"Y Deng","year":"2022","unstructured":"Deng Y, Li Y, Wen Z et al (2022) Morphing natural product platensimycin via heck, sonogashira, and one-pot sonogashira\/cycloaddition reactions to produce antibiotics with in vivo activity. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics11040425","journal-title":"Antibiotics"},{"key":"11402_CR25","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1021\/acscentsci.0c00122","volume":"6","author":"F Wu","year":"2020","unstructured":"Wu F, Zhang J, Song F et al (2020) Chrysomycin A derivatives for the treatment of multi-drug-resistant tuberculosis. ACS Cent Sci 6:928\u2013938. https:\/\/doi.org\/10.1021\/acscentsci.0c00122","journal-title":"ACS Cent Sci"},{"key":"11402_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s44321-023-00007-9","volume":"16","author":"A Vieira Da Cruz","year":"2024","unstructured":"Vieira Da Cruz A, Jim\u00e9nez-Castellanos JC, B\u00f6rnsen C et al (2024) Pyridylpiperazine efflux pump inhibitor boosts in vivo antibiotic efficacy against K. pneumoniae. EMBO Mol Med 16:93\u2013111. https:\/\/doi.org\/10.1038\/s44321-023-00007-9","journal-title":"EMBO Mol Med"},{"key":"11402_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116107","volume":"265","author":"J Zhang","year":"2024","unstructured":"Zhang J, Tan YM, Li SR et al (2024) Discovery of benzopyridone cyanoacetates as new type of potential broad-spectrum antibacterial candidates. Eur J Med Chem 265:116107. https:\/\/doi.org\/10.1016\/j.ejmech.2023.116107","journal-title":"Eur J Med Chem"},{"key":"11402_CR28","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1021\/acs.chemrev.0c01213","volume":"121","author":"JD Prajapati","year":"2021","unstructured":"Prajapati JD, Kleinekath\u00f6fer U, Winterhalter M (2021) How to enter a bacterium: bacterial porins and the permeation of antibiotics. Chem Rev 121:5158\u20135192. https:\/\/doi.org\/10.1021\/acs.chemrev.0c01213","journal-title":"Chem Rev"},{"key":"11402_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01390","author":"C Xu","year":"2020","unstructured":"Xu C, Wang D, Zhang X et al (2020) Mechanisms for rapid evolution of carbapenem resistance in a clinical isolate of Pseudomonas aeruginosa. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2020.01390","journal-title":"Front Microbiol"},{"key":"11402_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/mmbr.00193-23","author":"A Schumann","year":"2024","unstructured":"Schumann A, Gaballa A, Wiedmann M (2024) The multifaceted roles of phosphoethanolamine-modified lipopolysaccharides: from stress response and virulence to cationic antimicrobial resistance. Microbiol Mol Biol Rev. https:\/\/doi.org\/10.1128\/mmbr.00193-23","journal-title":"Microbiol Mol Biol Rev"},{"key":"11402_CR31","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/jac\/dkad063","volume":"78","author":"L Kime","year":"2023","unstructured":"Kime L, Waring T, Mohamad M et al (2023) Resistance to antibacterial antifolates in multidrug-resistant staphylococcus aureus\u202f: prevalence estimates and genetic basis. J Antimicrob Chemother 78:1201\u20131210. https:\/\/doi.org\/10.1093\/jac\/dkad063","journal-title":"J Antimicrob Chemother"},{"key":"11402_CR32","doi-asserted-by":"crossref","unstructured":"Zeden MS, Gallagher LA, Bueno E, et al (2023) Metabolic reprogramming and flux to cell envelope precursors in a pentose phosphate pathway mutant increases MRSA resistance to \u03b2-lactam antibiotics","DOI":"10.1101\/2023.03.03.530734"},{"key":"11402_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125574","volume":"26","author":"C Acierno","year":"2025","unstructured":"Acierno C, Barletta F, Nevola R et al (2025) Metabolic rewiring of bacterial pathogens in response to antibiotic pressure\u2014a molecular perspective. Int J Mol Sci 26:5574. https:\/\/doi.org\/10.3390\/ijms26125574","journal-title":"Int J Mol Sci"},{"key":"11402_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/biology14020165","volume":"14","author":"A Almatroudi","year":"2025","unstructured":"Almatroudi A (2025) Biofilm resilience: molecular mechanisms driving antibiotic resistance in clinical contexts. Biology 14:165. https:\/\/doi.org\/10.3390\/biology14020165","journal-title":"Biology"},{"key":"11402_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioflm.2023.100129","volume":"5","author":"M Fern\u00e1ndez-Bill\u00f3n","year":"2023","unstructured":"Fern\u00e1ndez-Bill\u00f3n M, Llamb\u00edas-Cabot AE, Jordana-Lluch E et al (2023) Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms. Biofilm 5:100129. https:\/\/doi.org\/10.1016\/j.bioflm.2023.100129","journal-title":"Biofilm"},{"key":"11402_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/life10110253","volume":"10","author":"JA Koch","year":"2020","unstructured":"Koch JA, Pust TM, Cappellini AJ et al (2020) Staphylococcus epidermidis biofilms have a high tolerance to antibiotics in periprosthetic joint infection. Life 10:253. https:\/\/doi.org\/10.3390\/life10110253","journal-title":"Life"},{"key":"11402_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1200923","author":"AS Oliveira","year":"2023","unstructured":"Oliveira AS, Saraiva LM, Carvalho SM (2023) Staphylococcus epidermidis biofilms undergo metabolic and matrix remodeling under nitrosative stress. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2023.1200923","journal-title":"Front Cell Infect Microbiol"},{"key":"11402_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1583112","author":"JPR Furlan","year":"2025","unstructured":"Furlan JPR, Zarrilli R, Daoud Z et al (2025) Editorial: global dissemination and evolution of epidemic multidrug-resistant gram-negative bacterial pathogens: surveillance, diagnosis and treatment, volume III. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2025.1583112","journal-title":"Front Microbiol"},{"key":"11402_CR39","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1111\/1462-2920.16481","volume":"25","author":"M Shintani","year":"2023","unstructured":"Shintani M, Vestergaard G, Milakovi\u0107 M et al (2023) Integrons, transposons and <scp>IS<\/scp> elements promote diversification of multidrug resistance plasmids and adaptation of their hosts to antibiotic pollutants from pharmaceutical companies. Environ Microbiol 25:3035\u20133051. https:\/\/doi.org\/10.1111\/1462-2920.16481","journal-title":"Environ Microbiol"},{"key":"11402_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/1751-7915.14408","author":"M Tokuda","year":"2024","unstructured":"Tokuda M, Shintani M (2024) Microbial evolution through horizontal gene transfer by mobile genetic elements. Microb Biotechnol. https:\/\/doi.org\/10.1111\/1751-7915.14408","journal-title":"Microb Biotechnol"},{"key":"11402_CR41","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","volume":"616","author":"AV Sadybekov","year":"2023","unstructured":"Sadybekov AV, Katritch V (2023) Computational approaches streamlining drug discovery. Nature 616:673\u2013685. https:\/\/doi.org\/10.1038\/s41586-023-05905-z","journal-title":"Nature"},{"key":"11402_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/jb.00127-23","volume":"205","author":"J Arnold","year":"2023","unstructured":"Arnold J, Glazier J, Mimee M (2023) Genetic engineering of resident bacteria in the gut microbiome. J Bacteriol 205:1\u201315. https:\/\/doi.org\/10.1128\/jb.00127-23","journal-title":"J Bacteriol"},{"key":"11402_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fchem.2020.00286","volume":"8","author":"YC Yeh","year":"2020","unstructured":"Yeh YC, Huang TH, Yang SC et al (2020) Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: A review of recent advances. Front Chem 8:1\u201322. https:\/\/doi.org\/10.3389\/fchem.2020.00286","journal-title":"Front Chem"},{"key":"11402_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041052","author":"P Aytar \u00c7elik","year":"2023","unstructured":"Aytar \u00c7elik P, Erdogan-Gover K, Barut D et al (2023) Bacterial membrane vesicles as smart drug delivery and carrier systems: a new nanosystems tool for current anticancer and antimicrobial therapy. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15041052","journal-title":"Pharmaceutics"},{"key":"11402_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph16111615","volume":"16","author":"G Muteeb","year":"2023","unstructured":"Muteeb G, Rehman MT, Shahwan M, Aatif M (2023) Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review. Pharmaceuticals 16:1\u201354. https:\/\/doi.org\/10.3390\/ph16111615","journal-title":"Pharmaceuticals"},{"key":"11402_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-024-10214-4","volume":"25","author":"M Nsubuga","year":"2024","unstructured":"Nsubuga M, Galiwango R, Jjingo D, Mboowa G (2024) Generalizability of machine learning in predicting antimicrobial resistance in E. coli: a multi-country case study in Africa. BMC Genomics 25:287. https:\/\/doi.org\/10.1186\/s12864-024-10214-4","journal-title":"BMC Genomics"},{"key":"11402_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12863-025-01338-x","volume":"26","author":"Y Xu","year":"2025","unstructured":"Xu Y, Mao Y, Hua X et al (2025) Machine learning-based prediction of antimicrobial resistance and identification of AMR-related SNPs in mycobacterium tuberculosis. BMC Genom Data 26:48. https:\/\/doi.org\/10.1186\/s12863-025-01338-x","journal-title":"BMC Genom Data"},{"key":"11402_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-018-0401-z","volume":"6","author":"G Arango-Argoty","year":"2018","unstructured":"Arango-Argoty G, Garner E, Pruden A et al (2018) DeepARG: a deep learning approach for predicting antibiotic resistance genes from metagenomic data. Microbiome 6:23. https:\/\/doi.org\/10.1186\/s40168-018-0401-z","journal-title":"Microbiome"},{"key":"11402_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0324836","volume":"20","author":"E Noumi","year":"2025","unstructured":"Noumi E, Snoussi M, Bouali N et al (2025) Structure-based virtual screening, molecular docking, and MD simulation studies: an in-silico approach for identifying potential MBL inhibitors. PLoS ONE 20:e0324836. https:\/\/doi.org\/10.1371\/journal.pone.0324836","journal-title":"PLoS ONE"},{"key":"11402_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/life14020233","volume":"14","author":"AI Visan","year":"2024","unstructured":"Visan AI, Negut I (2024) Integrating artificial intelligence for drug discovery in the context of revolutionizing drug delivery. Life 14:233. https:\/\/doi.org\/10.3390\/life14020233","journal-title":"Life"},{"key":"11402_CR51","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S, van Veenhuyzen D, Echols R et al (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18:1319\u20131328. https:\/\/doi.org\/10.1016\/S1473-3099(18)30554-1","journal-title":"Lancet Infect Dis"},{"key":"11402_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/PHAR.2203","volume":"39","author":"KM Shaeer","year":"2019","unstructured":"Shaeer KM, Zmarlicka MT, Chahine EB et al (2019) Plazomicin: a next-generation aminoglycoside. Pharmacotherapy 39:77\u201393. https:\/\/doi.org\/10.1002\/PHAR.2203","journal-title":"Pharmacotherapy"},{"key":"11402_CR53","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1358\/DOT.2017.53.10.2721815","volume":"53","author":"MW McCarthy","year":"2017","unstructured":"McCarthy MW, Walsh TJ (2017) Meropenem\/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections. Drugs Today (Barc) 53:521\u2013530. https:\/\/doi.org\/10.1358\/DOT.2017.53.10.2721815","journal-title":"Drugs Today (Barc)"},{"key":"11402_CR54","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/cid\/ciz090","volume":"69","author":"TM File","year":"2019","unstructured":"File TM, Goldberg L, Das A et al (2019) Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial. Clin Infect Dis 69:1856\u20131867. https:\/\/doi.org\/10.1093\/cid\/ciz090","journal-title":"Clin Infect Dis"},{"key":"11402_CR55","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/S40265-021-01576-0","volume":"81","author":"SM Hoy","year":"2021","unstructured":"Hoy SM (2021) Contezolid: first approval. Drugs 81:1587. https:\/\/doi.org\/10.1007\/S40265-021-01576-0","journal-title":"Drugs"},{"key":"11402_CR56","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1358\/DOT.2018.54.11.2878151","volume":"54","author":"G Kaul","year":"2018","unstructured":"Kaul G, Kapoor E, Dasgupta A, Chopra S (2018) Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Drugs Today (Barc) 54:657\u2013666. https:\/\/doi.org\/10.1358\/DOT.2018.54.11.2878151","journal-title":"Drugs Today (Barc)"},{"key":"11402_CR57","unstructured":"Silas Inman (2016) FDA Rejects Solithromycin for Bacterial Pneumonia | HCP Live. https:\/\/www.hcplive.com\/view\/fda-rejects-solithromycin-for-bacterial-pneumonia. Accessed 12 Sep 2025"},{"key":"11402_CR58","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/B978-1-4557-4801-3.00035-7","volume":"1","author":"GR Barber","year":"2015","unstructured":"Barber GR, Safdar A (2015) Unique antibacterial agents. Mandell Douglas Bennett\u2019s Prin Practice Infectious Dis 1:440-446.e2. https:\/\/doi.org\/10.1016\/B978-1-4557-4801-3.00035-7","journal-title":"Mandell Douglas Bennett\u2019s Prin Practice Infectious Dis"},{"key":"11402_CR59","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1021\/ACSINFECDIS.0C00021","volume":"6","author":"PA Bradford","year":"2020","unstructured":"Bradford PA, Miller AA, O\u2019Donnell J, Mueller JP (2020) Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates. ACS Infect Dis 6:1332\u20131345. https:\/\/doi.org\/10.1021\/ACSINFECDIS.0C00021","journal-title":"ACS Infect Dis"},{"key":"11402_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107357","author":"J Li","year":"2025","unstructured":"Li J, Wei F, Xiang P et al (2025) A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem\/cilastatin\/relebactam (IMI\/REL) vs piperacillin\/tazobactam (PIP\/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP). Int J Infect Dis. https:\/\/doi.org\/10.1016\/j.ijid.2024.107357","journal-title":"Int J Infect Dis"},{"key":"11402_CR61","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/S10096-019-03590-3","volume":"38","author":"YR Lee","year":"2019","unstructured":"Lee YR, Burton CE (2019) Eravacycline, a newly approved fluorocycline. Eur J Clin Microbiol Infect Dis 38:1787\u20131794. https:\/\/doi.org\/10.1007\/S10096-019-03590-3","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"11402_CR62","unstructured":"GSK (2025) Gepotidacin accepted for priority review by the US FDA for the oral treatment of uncomplicated urogenital gonorrhoea | GSK. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gepotidacin-accepted-for-priority-review-by-the-us-fda-for-the-oral-treatment-of-uncomplicated-urogenital-gonorrhoea\/. Accessed 12 Sep 2025"},{"key":"11402_CR63","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1473-3099(17)30235-9","volume":"17","author":"RJ Vickers","year":"2017","unstructured":"Vickers RJ, Tillotson GS, Nathan R et al (2017) Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis 17:735. https:\/\/doi.org\/10.1016\/S1473-3099(17)30235-9","journal-title":"Lancet Infect Dis"},{"key":"11402_CR64","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/INF.0000000000004807","volume":"44","author":"R Mngqibisa","year":"2025","unstructured":"Mngqibisa R, Fofanov O, Grazioso CF et al (2025) A phase 3 study of the safety and efficacy of tedizolid phosphate in patients <12 years of age with acute bacterial skin and skin structure infections. Pediatr Infect Dis J 44:533\u2013538. https:\/\/doi.org\/10.1097\/INF.0000000000004807","journal-title":"Pediatr Infect Dis J"},{"key":"11402_CR65","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00250-20","volume":"64","author":"F Wittke","year":"2020","unstructured":"Wittke F, Vincent C, Chen J et al (2020) Afabicin, a first-in-class antistaphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: clinical noninferiority to vancomycin\/linezolid. Antimicrob Agents Chemother 64:e00250-20. https:\/\/doi.org\/10.1128\/AAC.00250-20","journal-title":"Antimicrob Agents Chemother"},{"key":"11402_CR66","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01078-19","volume":"63","author":"A Watson","year":"2019","unstructured":"Watson A, Oh JT, Sauve K et al (2019) Antimicrobial activity of exebacase (lysin CF-301) against the most common causes of infective endocarditis. Antimicrob Agents Chemother 63:e01078-19. https:\/\/doi.org\/10.1128\/AAC.01078-19","journal-title":"Antimicrob Agents Chemother"},{"key":"11402_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115738","author":"A de Jes\u00fas Dzul-Beh","year":"2023","unstructured":"de Jes\u00fas Dzul-Beh A, Uc-Cach\u00f3n AH, Gonz\u00e1lez-S\u00e1nchez AA et al (2023) Antimicrobial potential of the Mayan medicine plant Matayba oppositifolia (A. Rich.) Britton against antibiotic-resistant priority pathogens. J Ethnopharmacol. https:\/\/doi.org\/10.1016\/j.jep.2022.115738","journal-title":"J Ethnopharmacol"},{"key":"11402_CR68","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1895340","author":"S Manandhar","year":"2019","unstructured":"Manandhar S, Luitel S, Dahal RK (2019) In vitro antimicrobial activity of some medicinal plants against human pathogenic bacteria. J Trop Med. https:\/\/doi.org\/10.1155\/2019\/1895340","journal-title":"J Trop Med"},{"key":"11402_CR69","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1007\/s00044-023-03071-5","volume":"32","author":"S Egra","year":"2023","unstructured":"Egra S, Kuspradini H, Kusuma IW et al (2023) Garcidepsidone B from garcinia parvifolia: antimicrobial activities of the medicinal plants from east and North Kalimantan against dental caries and periodontal disease pathogen. Med Chem Res 32:1658\u20131665. https:\/\/doi.org\/10.1007\/s00044-023-03071-5","journal-title":"Med Chem Res"},{"key":"11402_CR70","first-page":"21","volume":"1","author":"N Srivastava","year":"2013","unstructured":"Srivastava N, Kainthola A, Bhatt AB (2013) In vitro antimicrobial activity of bark of Z. armatum DC against Human Pathogens. Int J Herb Med 1:21\u201324","journal-title":"Int J Herb Med"},{"key":"11402_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0293361","volume":"18","author":"YD Zhang","year":"2023","unstructured":"Zhang YD, Liu LY, Wang D et al (2023) Isolation and identification of bioactive compounds from antrodia camphorata against ESKAPE pathogens. PLoS ONE 18:1\u201315. https:\/\/doi.org\/10.1371\/journal.pone.0293361","journal-title":"PLoS ONE"},{"key":"11402_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox11112174","volume":"11","author":"M Snoussi","year":"2022","unstructured":"Snoussi M, Ahmad I, Aljohani AMA et al (2022) Phytochemical analysis, antioxidant, and antimicrobial activities of ducrosia flabellifolia: A combined experimental and computational approaches. Antioxidants 11:1\u201320. https:\/\/doi.org\/10.3390\/antiox11112174","journal-title":"Antioxidants"},{"key":"11402_CR73","doi-asserted-by":"publisher","first-page":"43024","DOI":"10.1021\/acsomega.3c06246","volume":"8","author":"M Getahun","year":"2023","unstructured":"Getahun M, Nesru Y, Ahmed M et al (2023) Phytochemical composition, antioxidant, antimicrobial, antibiofilm, and antiquorum sensing potential of methanol extract and essential oil from Acanthus polystachyus delile (Acanthaceae). ACS Omega 8:43024\u201343036. https:\/\/doi.org\/10.1021\/acsomega.3c06246","journal-title":"ACS Omega"},{"key":"11402_CR74","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1021\/acs.jnatprod.1c00578","volume":"84","author":"MT Meenu","year":"2021","unstructured":"Meenu MT, Kaul G, Shukla M et al (2021) Cudraflavone C from Artocarpus hirsutus as a promising inhibitor of pathogenic, multidrug-resistant S. aureus, persisters, and biofilms: a new insight into a rational explanation of traditional wisdom. J Nat Prod 84:2700\u20132708. https:\/\/doi.org\/10.1021\/acs.jnatprod.1c00578","journal-title":"J Nat Prod"},{"key":"11402_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-021-00343-2","volume":"8","author":"Q-Y Zhang","year":"2021","unstructured":"Zhang Q-Y, Yan Z-B, Meng Y-M et al (2021) Antimicrobial peptides: mechanism of action, activity and clinical potential. Mil Med Res 8:48. https:\/\/doi.org\/10.1186\/s40779-021-00343-2","journal-title":"Mil Med Res"},{"key":"11402_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2025.108570","volume":"81","author":"R Yang","year":"2025","unstructured":"Yang R, Ma X, Peng F et al (2025) Advances in antimicrobial peptides: from mechanistic insights to chemical modifications. Biotechnol Adv 81:108570. https:\/\/doi.org\/10.1016\/j.biotechadv.2025.108570","journal-title":"Biotechnol Adv"},{"key":"11402_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38079","volume":"10","author":"KR G","year":"2024","unstructured":"G KR, Narasingappa RB, Vyas GV (2024) Unveiling mechanisms of antimicrobial peptide: actions beyond the membranes disruption. Hel 10:e38079. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38079","journal-title":"Hel"},{"key":"11402_CR78","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/2472555218812657","volume":"24","author":"MI Konaklieva","year":"2019","unstructured":"Konaklieva MI (2019) Addressing antimicrobial resistance through new medicinal and synthetic chemistry strategies. SLAS Discov 24:419\u2013439. https:\/\/doi.org\/10.1177\/2472555218812657","journal-title":"SLAS Discov"},{"key":"11402_CR79","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.14649","volume":"1496","author":"M Zhu","year":"2021","unstructured":"Zhu M, Tse MW, Weller J et al (2021) The future of antibiotics begins with discovering new combinations. Ann N Y Acad Sci 1496:82\u201396. https:\/\/doi.org\/10.1111\/nyas.14649","journal-title":"Ann N Y Acad Sci"},{"key":"11402_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27984","volume":"10","author":"N Morales-Dur\u00e1n","year":"2024","unstructured":"Morales-Dur\u00e1n N, Le\u00f3n-Buitimea A, Morones-Ram\u00edrez JR (2024) Unraveling resistance mechanisms in combination therapy: a comprehensive review of recent advances and future directions. Heliyon 10:e27984. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27984","journal-title":"Heliyon"},{"key":"11402_CR81","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/17460441.2016.1187597","volume":"11","author":"AL Parkes","year":"2016","unstructured":"Parkes AL, Yule IA (2016) Hybrid antibiotics \u2013 clinical progress and novel designs. Expert Opin Drug Discov 11:665\u2013680. https:\/\/doi.org\/10.1080\/17460441.2016.1187597","journal-title":"Expert Opin Drug Discov"},{"key":"11402_CR82","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","volume":"17","author":"M Tyers","year":"2019","unstructured":"Tyers M, Wright GD (2019) Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat Rev Microbiol 17:141\u2013155. https:\/\/doi.org\/10.1038\/s41579-018-0141-x","journal-title":"Nat Rev Microbiol"},{"key":"11402_CR83","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1139\/cjm-2017-0466","volume":"64","author":"AJ Clarke","year":"2018","unstructured":"Clarke AJ (2018) The \u201chole\u201d story of predatory outer-membrane vesicles. Can J Microbiol 64:589\u2013599. https:\/\/doi.org\/10.1139\/cjm-2017-0466","journal-title":"Can J Microbiol"},{"key":"11402_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108542","author":"AAQ Ahmed","year":"2023","unstructured":"Ahmed AAQ, Besio R, Xiao L, Forlino A (2023) Outer membrane vesicles (OMVs) as biomedical tools and their relevance as immune-modulating agents against H. pylori infections: current status and future prospects. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24108542","journal-title":"Int J Mol Sci"},{"key":"11402_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2011.00185","volume":"2","author":"L Good","year":"2011","unstructured":"Good L, Stach JEM (2011) Synthetic RNA silencing in bacteria - antimicrobial discovery and resistance breaking. Front Microbiol 2:1\u201311. https:\/\/doi.org\/10.3389\/fmicb.2011.00185","journal-title":"Front Microbiol"},{"key":"11402_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fddsv.2024.1385460","volume":"4","author":"B Singha","year":"2024","unstructured":"Singha B, Singh V, Soni V (2024) Alternative therapeutics to control antimicrobial resistance: a general perspective. Front Drug Discov 4:1\u201317. https:\/\/doi.org\/10.3389\/fddsv.2024.1385460","journal-title":"Front Drug Discov"},{"key":"11402_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1009672","volume":"17","author":"DP Araya","year":"2021","unstructured":"Araya DP, Palmer KL, Duerkop BA (2021) CRISPR-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria. PLoS Pathog 17:1\u20138. https:\/\/doi.org\/10.1371\/journal.ppat.1009672","journal-title":"PLoS Pathog"},{"key":"11402_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.716064","author":"C Duan","year":"2021","unstructured":"Duan C, Cao H, Zhang LH, Xu Z (2021) Harnessing the CRISPR-Cas systems to combat antimicrobial resistance. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2021.716064","journal-title":"Front Microbiol"},{"key":"11402_CR89","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S247271","author":"P Gholizadeh","year":"2020","unstructured":"Gholizadeh P, Dao S, Ganbarov K et al (2020) How CRISPR-Cas system could be used to combat antimicrobial resistance. Infect Drug Resist. https:\/\/doi.org\/10.2147\/IDR.S247271","journal-title":"Infect Drug Resist"},{"key":"11402_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13121141","volume":"13","author":"C de la Fuente Tagarro","year":"2024","unstructured":"de la Fuente Tagarro C, Mart\u00edn-Gonz\u00e1lez D, De Lucas A et al (2024) Current knowledge on CRISPR strategies against antimicrobial-resistant bacteria. Antibiotics 13:1141. https:\/\/doi.org\/10.3390\/antibiotics13121141","journal-title":"Antibiotics"},{"key":"11402_CR91","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13756-020-00795-6","volume":"9","author":"B Aslam","year":"2020","unstructured":"Aslam B, Rasool M, Idris A et al (2020) CRISPR-Cas system: A potential alternative tool to cope antibiotic resistance. Antimicrob Resist Infect Control 9:6\u20138. https:\/\/doi.org\/10.1186\/s13756-020-00795-6","journal-title":"Antimicrob Resist Infect Control"},{"key":"11402_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics10070756","volume":"10","author":"MG de Aledo","year":"2021","unstructured":"de Aledo MG, Gonz\u00e1lez-Bardanca M, Blasco L et al (2021) Crispr-cas, a revolution in the treatment and study of eskape infections: Pre-clinical studies. Antibiotics 10:1\u201323. https:\/\/doi.org\/10.3390\/antibiotics10070756","journal-title":"Antibiotics"},{"key":"11402_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-16731-6","volume":"11","author":"K Kiga","year":"2020","unstructured":"Kiga K, Tan XE, Ibarra-Ch\u00e1vez R et al (2020) Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. Nat Commun 11:1\u201311. https:\/\/doi.org\/10.1038\/s41467-020-16731-6","journal-title":"Nat Commun"},{"key":"11402_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics13030352","volume":"13","author":"F Wan","year":"2021","unstructured":"Wan F, Draz MS, Gu M et al (2021) Novel strategy to combat antibiotic resistance: A sight into the combination of crispr\/cas9 and nanoparticles. Pharmaceutics 13:1\u201319. https:\/\/doi.org\/10.3390\/pharmaceutics13030352","journal-title":"Pharmaceutics"},{"key":"11402_CR95","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1021\/ac203233q","volume":"84","author":"FP Zamborini","year":"2012","unstructured":"Zamborini FP, Bao L, Dasari R (2012) Nanoparticles in measurement science. Anal Chem 84:541\u2013576. https:\/\/doi.org\/10.1021\/ac203233q","journal-title":"Anal Chem"},{"key":"11402_CR96","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2147\/IJN.S121956","volume":"12","author":"L Wang","year":"2017","unstructured":"Wang L, Hu C, Shao L (2017) The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int J Nanomedicine 12:1227\u20131249. https:\/\/doi.org\/10.2147\/IJN.S121956","journal-title":"Int J Nanomedicine"},{"key":"11402_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-017-0308-z","volume":"15","author":"YN Slavin","year":"2017","unstructured":"Slavin YN, Asnis J, H\u00e4feli UO, Bach H (2017) Metal nanoparticles: understanding the mechanisms behind antibacterial activity. J Nanobiotechnology 15:1\u201320. https:\/\/doi.org\/10.1186\/s12951-017-0308-z","journal-title":"J Nanobiotechnology"},{"key":"11402_CR98","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1166\/jnn.2014.9054","volume":"14","author":"A Herman","year":"2014","unstructured":"Herman A, Herman AP (2014) Nanoparticles as antimicrobial agents: their toxicity and mechanisms of action. J Nanosci Nanotechnol 14:946\u2013957. https:\/\/doi.org\/10.1166\/jnn.2014.9054","journal-title":"J Nanosci Nanotechnol"},{"key":"11402_CR99","doi-asserted-by":"publisher","first-page":"9322","DOI":"10.1021\/am402618w","volume":"5","author":"DL Slomberg","year":"2013","unstructured":"Slomberg DL, Lu Y, Broadnax AD et al (2013) Role of size and shape on biofilm eradication for nitric oxide-releasing silica nanoparticles. ACS Appl Mater Interfaces 5:9322\u20139329. https:\/\/doi.org\/10.1021\/am402618w","journal-title":"ACS Appl Mater Interfaces"},{"key":"11402_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123084","author":"A Sarwar","year":"2015","unstructured":"Sarwar A, Katas H, Samsudin SN, Zin NM (2015) Regioselective sequential modification of chitosan via azide-alkyne click reaction: synthesis, characterization, and antimicrobial activity of chitosan derivatives and nanoparticles. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0123084","journal-title":"PLoS One"},{"key":"11402_CR101","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.2147\/IJN.S24805","volume":"7","author":"JT Seil","year":"2012","unstructured":"Seil JT, Webster TJ (2012) Antimicrobial applications of nanotechnology: methods and literature. Int J Nanomedicine 7:2767\u20132781. https:\/\/doi.org\/10.2147\/IJN.S24805","journal-title":"Int J Nanomedicine"},{"key":"11402_CR102","unstructured":"Mezher M FDA Adds Three New Pathogens to GAIN Act Qualifying List, But Impact Remains Unclear. RAPS"},{"key":"11402_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-025-01109-4","volume":"21","author":"L Moja","year":"2025","unstructured":"Moja L, Abbas M, de Kraker ME et al (2025) Reserve antibiotics: overcoming limitations of evidence generated from regulatory approval trials. Global Health 21:17. https:\/\/doi.org\/10.1186\/s12992-025-01109-4","journal-title":"Global Health"},{"key":"11402_CR104","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/84981","volume":"8","author":"MC Orencia","year":"2001","unstructured":"Orencia MC, Yoon JS, Ness JE et al (2001) Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat Struct Biol 8:238\u2013242. https:\/\/doi.org\/10.1038\/84981","journal-title":"Nat Struct Biol"},{"key":"11402_CR105","doi-asserted-by":"publisher","unstructured":"Philippon A, Arlet G, Jacoby GA (2002) Plasmid-Determined AmpC-Type \u2424 -Lactamases 46:1\u201311. https:\/\/doi.org\/10.1128\/AAC.46.1.1","DOI":"10.1128\/AAC.46.1.1"},{"key":"11402_CR106","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.bcp.2007.05.021","volume":"74","author":"C Bebrone","year":"2007","unstructured":"Bebrone C (2007) Metallo-\u03b2-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. Biochem Pharmacol 74:1686\u20131701. https:\/\/doi.org\/10.1016\/j.bcp.2007.05.021","journal-title":"Biochem Pharmacol"},{"key":"11402_CR107","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1021\/bi201790u","volume":"51","author":"M Morar","year":"2012","unstructured":"Morar M, Pengelly K, Koteva K, Wright GD (2012) Mechanism and diversity of the erythromycin esterase family of enzymes. Biochemistry 51:1740\u20131751. https:\/\/doi.org\/10.1021\/bi201790u","journal-title":"Biochemistry"},{"key":"11402_CR108","doi-asserted-by":"publisher","first-page":"10715","DOI":"10.1039\/b000000x","volume":"3","author":"F Paquin","year":"2015","unstructured":"Paquin F, Rivnay J, Salleo A et al (2015) Multi-phase semicrystalline microstructures drive exciton dissociation in neat plastic semiconductors. J Mater Chem C 3:10715\u201310722. https:\/\/doi.org\/10.1039\/b000000x","journal-title":"J Mater Chem C"},{"key":"11402_CR109","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.addr.2005.04.002","volume":"57","author":"GD Wright","year":"2005","unstructured":"Wright GD (2005) Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv Drug Deliv Rev 57:1451\u20131470. https:\/\/doi.org\/10.1016\/j.addr.2005.04.002","journal-title":"Adv Drug Deliv Rev"},{"key":"11402_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/1040841X.2015.1136261","volume":"43","author":"C Gomes","year":"2017","unstructured":"Gomes C, Mart\u00ednez-Puchol S, Palma N et al (2017) Macrolide resistance mechanisms in enterobacteriaceae: focus on azithromycin. Crit Rev Microbiol 43:1\u201330. https:\/\/doi.org\/10.3109\/1040841X.2015.1136261","journal-title":"Crit Rev Microbiol"},{"key":"11402_CR111","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-genet-102209-163517","volume":"44","author":"M Morar","year":"2010","unstructured":"Morar M, Wright GD (2010) The genomic enzymology of antibiotic resistance. Annu Rev Genet 44:25\u201351. https:\/\/doi.org\/10.1146\/annurev-genet-102209-163517","journal-title":"Annu Rev Genet"},{"key":"11402_CR112","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/pro.2414","volume":"23","author":"I Nikolaidis","year":"2014","unstructured":"Nikolaidis I, Favini-Stabile S, Dessen A (2014) Resistance to antibiotics targeted to the bacterial cell wall. Protein Sci 23:243\u2013259. https:\/\/doi.org\/10.1002\/pro.2414","journal-title":"Protein Sci"},{"key":"11402_CR113","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1473-3099(18)30614-5","volume":"19","author":"DN Gerding","year":"2019","unstructured":"Gerding DN, Cornely OA, Grill S et al (2019) Cadazolid for the treatment of clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infect Dis 19:265\u2013274. https:\/\/doi.org\/10.1016\/S1473-3099(18)30614-5","journal-title":"Lancet Infect Dis"},{"key":"11402_CR114","unstructured":"Iclaprim (2025) Study Details | NCT02600611 | Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1 | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02600611. Accessed 12 Sep 2025"},{"key":"11402_CR115","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2147\/IDR.S453634","volume":"17","author":"D Shimada","year":"2024","unstructured":"Shimada D, Seki M (2024) Effectiveness of drip infusion of lascufloxacin, a novel fluoroquinolone antibiotic, for patients with pneumonia including chronic lung disease exacerbations and lung abscesses. Infect Drug Resist 17:911\u2013918. https:\/\/doi.org\/10.2147\/IDR.S453634","journal-title":"Infect Drug Resist"},{"key":"11402_CR116","unstructured":"U.S. FDA EMBLAVEO (2025) U.S. FDA Approves EMBLAVEOTM (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options - Feb 7, 2025. https:\/\/news.abbvie.com\/2025-02-07-U-S-FDA-Approves-EMBLAVEO-TM-aztreonam-and-avibactam-for-the-Treatment-of-Adults-With-Complicated-Intra-Abdominal-Infections-With-Limited-or-No-Treatment-Options. Accessed 12 Sep 2025"},{"key":"11402_CR117","unstructured":"FDA U.S Food and Drug Administration (2024) FDA approves new treatment for uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibiotic treatment options | FDA. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-treatment-uncomplicated-urinary-tract-infections-adult-women-who-have-limited-or-no. Accessed 12 Sep 2025"},{"key":"11402_CR118","unstructured":"GSK (2025) Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older | GSK. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections\/. Accessed 12 Sep 2025"},{"key":"11402_CR119","unstructured":"Chris Dall M (2025) Roche to launch phase 3 trial for new antibiotic targeting Acinetobacter baumannii | CIDRAP. https:\/\/www.cidrap.umn.edu\/antimicrobial-stewardship\/roche-launch-phase-3-trial-new-antibiotic-targeting-acinetobacter. Accessed 12 Sep 2025"},{"key":"11402_CR120","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202503023","author":"S Li","year":"2025","unstructured":"Li S, Wang K, Shi W et al (2025) Vm\u2013MSI: A vancomycin-antimicrobial peptide conjugate combating resistant bacteria and broadening the antimicrobial spectrum. Adv Sci. https:\/\/doi.org\/10.1002\/advs.202503023","journal-title":"Adv Sci"},{"key":"11402_CR121","unstructured":"Patel S, Saw S (2025) Daptomycin"},{"key":"11402_CR122","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/AAC.01009-09","volume":"54","author":"K Bush","year":"2010","unstructured":"Bush K, Jacoby GA (2010) Updated functional classification of \u03b2-lactamases. Antimicrob Agents Chemother 54:969\u2013976. https:\/\/doi.org\/10.1128\/AAC.01009-09","journal-title":"Antimicrob Agents Chemother"},{"key":"11402_CR123","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1093\/bioinformatics\/btaa095","volume":"36","author":"GA Arango-Argoty","year":"2020","unstructured":"Arango-Argoty GA, Guron GKP, Guron GKP et al (2020) Argminer: a web platform for the crowdsourcing-based curation of antibiotic resistance genes. Bioinformatics 36:2966\u20132973. https:\/\/doi.org\/10.1093\/bioinformatics\/btaa095","journal-title":"Bioinformatics"},{"key":"11402_CR124","doi-asserted-by":"publisher","first-page":"100","DOI":"10.7868\/s0453881114010183","volume":"55","author":"AN Zhang","year":"2020","unstructured":"Zhang AN, Hou CJ, Negi M, Li LG, Zhang T (2020) Online searching platform for the antibiotic resistome in bacterial tree of life and global habitats. FEMS Microbiol Ecol 55:100\u2013106. https:\/\/doi.org\/10.7868\/s0453881114010183","journal-title":"FEMS Microbiol Ecol"},{"key":"11402_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2020.00052","volume":"11","author":"LG Panunzi","year":"2020","unstructured":"Panunzi LG (2020) Srax: a novel comprehensive resistome analysis tool. Front Microbiol 11:1\u201311. https:\/\/doi.org\/10.3389\/fmicb.2020.00052","journal-title":"Front Microbiol"},{"key":"11402_CR126","doi-asserted-by":"publisher","first-page":"D517","DOI":"10.1093\/nar\/gkz935","volume":"48","author":"BP Alcock","year":"2020","unstructured":"Alcock BP, Raphenya AR, Lau TTY et al (2020) Card 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res 48:D517\u2013D525. https:\/\/doi.org\/10.1093\/nar\/gkz935","journal-title":"Nucleic Acids Res"},{"key":"11402_CR127","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00483-19","author":"M Feldgarden","year":"2019","unstructured":"Feldgarden M, Brover V, Haft DH et al (2019) Validating the AMRFINder tool and resistance gene database by using antimicrobial resistance genotype-phenotype correlations in a collection of isolates. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00483-19","journal-title":"Antimicrob Agents Chemother"},{"key":"11402_CR128","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.envint.2019.04.030","volume":"128","author":"Z Wei","year":"2019","unstructured":"Wei Z, Wu Y, Feng K et al (2019) ARGA, a pipeline for primer evaluation on antibiotic resistance genes. Environ Int 128:137\u2013145. https:\/\/doi.org\/10.1016\/j.envint.2019.04.030","journal-title":"Environ Int"},{"key":"11402_CR129","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41573-022-00521-4","volume":"21","author":"JL Childs-Disney","year":"2022","unstructured":"Childs-Disney JL, Yang X, Gibaut QMR et al (2022) Targeting RNA structures with small molecules. Nat Rev Drug Discov 21:736\u2013762. https:\/\/doi.org\/10.1038\/s41573-022-00521-4","journal-title":"Nat Rev Drug Discov"},{"key":"11402_CR130","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/jac\/dkz092","volume":"74","author":"H Hasman","year":"2019","unstructured":"Hasman H, Clausen PTLC, Kaya H et al (2019) LRE-finder, a web tool for detection of the 23S rRNA mutations and the optrA, cfr, cfr(B) and poxtA genes encoding linezolid resistance in enterococci from whole-genome sequences. J Antimicrob Chemother 74:1473\u20131476. https:\/\/doi.org\/10.1093\/jac\/dkz092","journal-title":"J Antimicrob Chemother"},{"key":"11402_CR131","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/jac\/dkx513","volume":"73","author":"SR Partridge","year":"2018","unstructured":"Partridge SR, Tsafnat G (2018) Automated annotation of mobile antibiotic resistance in Gram-negative bacteria: the multiple antibiotic resistance annotator (MARA) and database. J Antimicrob Chemother 73:883\u2013890. https:\/\/doi.org\/10.1093\/jac\/dkx513","journal-title":"J Antimicrob Chemother"},{"key":"11402_CR132","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/jac\/dky210","volume":"73","author":"Z Zong","year":"2018","unstructured":"Zong Z, Fenn S, Connor C et al (2018) Complete genomic characterization of two escherichia coli lineages responsible for a cluster of carbapenem-resistant infections in a Chinese hospital. J Antimicrob Chemother 73:2340\u20132346. https:\/\/doi.org\/10.1093\/jac\/dky210","journal-title":"J Antimicrob Chemother"},{"key":"11402_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-018-2336-6","volume":"19","author":"PTLC Clausen","year":"2018","unstructured":"Clausen PTLC, Aarestrup FM, Lund O (2018) Rapid and precise alignment of raw reads against redundant databases with KMA. BMC Bioinform 19:1\u20138. https:\/\/doi.org\/10.1186\/s12859-018-2336-6","journal-title":"BMC Bioinform"},{"key":"11402_CR134","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1093\/bioinformatics\/bty387","volume":"34","author":"WPM Rowe","year":"2018","unstructured":"Rowe WPM, Winn MD (2018) Indexed variation graphs for efficient and accurate resistome profiling. Bioinform 34:3601\u20133608. https:\/\/doi.org\/10.1093\/bioinformatics\/bty387","journal-title":"Bioinform"},{"key":"11402_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40168-018-0401-z","volume":"6","author":"G Arango-Argoty","year":"2018","unstructured":"Arango-Argoty G, Garner E, Pruden A et al (2018) Deeparg: a deep learning approach for predicting antibiotic resistance genes from metagenomic data. Microbiome 6:1\u201315. https:\/\/doi.org\/10.1186\/s40168-018-0401-z","journal-title":"Microbiome"},{"key":"11402_CR136","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1093\/bioinformatics\/bty053","volume":"34","author":"X Yin","year":"2018","unstructured":"Yin X, Jiang XT, Chai B et al (2018) ARGs-OAP v2.0 with an expanded SARG database and hidden Markov models for enhancement characterization and quantification of antibiotic resistance genes in environmental metagenomes. Bioinformatics 34:2263\u20132270. https:\/\/doi.org\/10.1093\/bioinformatics\/bty053","journal-title":"Bioinformatics"},{"key":"11402_CR137","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1021\/acsinfecdis.0c00190","volume":"6","author":"X Jiang","year":"2020","unstructured":"Jiang X, Zhang S, Azad MAK et al (2020) Structure-interaction relationship of polymyxins with the membrane of human kidney proximal tubular cells. ACS Infect Dis 6:2110\u20132119. https:\/\/doi.org\/10.1021\/acsinfecdis.0c00190","journal-title":"ACS Infect Dis"},{"key":"11402_CR138","unstructured":"WO2019239352A1 - Enhancement of antibacterial actions of a depsipeptide antibiotic using synergistic amounts of boric acid - Google Patents. https:\/\/patents.google.com\/patent\/WO2019239352A1\/en. Accessed 12 Dec 2025"},{"key":"11402_CR139","unstructured":"Study on promising new antibiotic Darobactin reinforces its potential | German Center for Infection Research. https:\/\/www.dzif.de\/en\/study-promising-new-antibiotic-darobactin-reinforces-its-potential. Accessed 12 Dec 2025"},{"key":"11402_CR140","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1021\/ACS.JMEDCHEM.4C03020","volume":"68","author":"Y He","year":"2025","unstructured":"He Y, Su J, Li M et al (2025) Discovery of cationic lugdunin derivatives with membrane-disrupting activity against resistant bacteria via radical reactions and amino acid mutations. J Med Chem 68:5699\u20135718. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.4C03020","journal-title":"J Med Chem"},{"key":"11402_CR141","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1021\/ACSSYNBIO.1C00080","volume":"10","author":"X Zhao","year":"2021","unstructured":"Zhao X, Kuipers OP (2021) Nisin- and ripcin-derived hybrid lanthipeptides display selective antimicrobial activity against staphylococcus aureus. ACS Synth Biol 10:1703. https:\/\/doi.org\/10.1021\/ACSSYNBIO.1C00080","journal-title":"ACS Synth Biol"},{"key":"11402_CR142","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.3390\/IJMS21186500","volume":"21","author":"X Ding","year":"2020","unstructured":"Ding X, Yu H, Qiao S (2020) Lasso peptide microcin J25 effectively enhances gut barrier function and modulates inflammatory response in an enterotoxigenic escherichia coli-challenged mouse model. Int J Mol Sci 21:6500. https:\/\/doi.org\/10.3390\/IJMS21186500","journal-title":"Int J Mol Sci"},{"key":"11402_CR143","doi-asserted-by":"publisher","DOI":"10.1007\/S00018-009-0129-9","volume":"66","author":"T Mogi","year":"2009","unstructured":"Mogi T, Kita K (2009) Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. Cell Mol Life Sci 66:3821. https:\/\/doi.org\/10.1007\/S00018-009-0129-9","journal-title":"Cell Mol Life Sci"},{"key":"11402_CR144","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1586\/14787210.4.6.939","volume":"4","author":"P Fulco","year":"2006","unstructured":"Fulco P, Wenzel RP (2006) Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev Anti-Infect Ther 4:939\u2013945. https:\/\/doi.org\/10.1586\/14787210.4.6.939","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"11402_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-39307-2.00033-3","author":"P Kumar","year":"2017","unstructured":"Kumar P (2017) Pharmacology of specific drug groups: antibiotic therapy. Pharmacol Ther Dentistry Seventh Ed. https:\/\/doi.org\/10.1016\/B978-0-323-39307-2.00033-3","journal-title":"Pharmacol Ther Dentistry Seventh Ed"},{"key":"11402_CR146","unstructured":"cyclotide kalata B1 | Ligand page | IUPHAR\/BPS Guide to PHARMACOLOGY. https:\/\/www.guidetopharmacology.org\/GRAC\/LigandDisplayForward?ligandId=13238. Accessed 12 Dec 2025"},{"key":"11402_CR147","doi-asserted-by":"publisher","first-page":"32637","DOI":"10.1074\/jbc.M805533200","volume":"283","author":"G Wang","year":"2008","unstructured":"Wang G (2008) Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J Biol Chem 283:32637\u201332643. https:\/\/doi.org\/10.1074\/jbc.M805533200","journal-title":"J Biol Chem"},{"key":"11402_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801654-1.00013-9","author":"BL Allen-Hoffmann","year":"2016","unstructured":"Allen-Hoffmann BL, Rooney PJ (2016) Current innovations for the treatment of chronic wounds. Skin Tissue Eng Regen Med. https:\/\/doi.org\/10.1016\/B978-0-12-801654-1.00013-9","journal-title":"Skin Tissue Eng Regen Med"},{"key":"11402_CR149","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1002\/CMDC.202000301","volume":"15","author":"R Kundu","year":"2020","unstructured":"Kundu R (2020) Cationic amphiphilic peptides: synthetic antimicrobial agents inspired by nature. ChemMedChem 15:1887\u20131896. https:\/\/doi.org\/10.1002\/CMDC.202000301","journal-title":"ChemMedChem"},{"key":"11402_CR150","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/PH18030289","volume":"18","author":"G Rizzetto","year":"2025","unstructured":"Rizzetto G, De SE, Molinelli E et al (2025) Protegrin-1 and analogues against acinetobacter baumannii: A narrative review. Pharmaceuticals 18:18. https:\/\/doi.org\/10.3390\/PH18030289","journal-title":"Pharmaceuticals"},{"key":"11402_CR151","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/J.CIMID.2016.10.004","volume":"49","author":"R Holani","year":"2016","unstructured":"Holani R, Shah C, Haji Q et al (2016) Proline-arginine rich (PR-39) cathelicidin: structure, expression and functional implication in intestinal health. Comp Immunol Microbiol Infect Dis 49:95\u2013101. https:\/\/doi.org\/10.1016\/J.CIMID.2016.10.004","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"11402_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS24065426","volume":"24","author":"LD D\u2019Andrea","year":"2023","unstructured":"D\u2019Andrea LD, Romanelli A, D\u2019Andrea LD, Romanelli A (2023) Temporins: multifunctional peptides from frog skin. Int J Mol Sci 24:24. https:\/\/doi.org\/10.3390\/IJMS24065426","journal-title":"Int J Mol Sci"},{"key":"11402_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS20235862","author":"D Brady","year":"2019","unstructured":"Brady D, Grapputo A, Romoli O et al (2019) Insect cecropins, antimicrobial peptides with potential therapeutic applications. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS20235862","journal-title":"Int J Mol Sci"},{"key":"11402_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114769","author":"S Guha","year":"2021","unstructured":"Guha S, Ferrie RP, Ghimire J et al (2021) Applications and evolution of melittin, the quintessential membrane active peptide. Biochem Pharmacol. https:\/\/doi.org\/10.1016\/j.bcp.2021.114769","journal-title":"Biochem Pharmacol"},{"key":"11402_CR155","unstructured":"Definition of omiganan pentahydrochloride - NCI Drug Dictionary - NCI. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/omiganan-pentahydrochloride. Accessed 15 Dec 2025"},{"key":"11402_CR156","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.AAN4044","author":"A De Breij","year":"2018","unstructured":"De Breij A, Riool M, Cordfunke RA et al (2018) The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms. Sci Transl Med. https:\/\/doi.org\/10.1126\/SCITRANSLMED.AAN4044","journal-title":"Sci Transl Med"},{"key":"11402_CR157","unstructured":"Polyphor\u2019s Pneumonia Antibiotic Abandoned in Phase III. https:\/\/www.labiotech.eu\/more-news\/polyphor-pneumonia-antibiotic-murepavadin\/. Accessed 15 Dec 2025"},{"key":"11402_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/MD17060376","volume":"17","author":"DS Orlov","year":"2019","unstructured":"Orlov DS, Shamova OV, Eliseev IE et al (2019) Redesigning arenicin-1, an antimicrobial peptide from the marine polychaeta arenicola marina, by strand rearrangement or branching, substitution of specific residues, and backbone linearization or cyclization. Mar Drugs 17:17. https:\/\/doi.org\/10.3390\/MD17060376","journal-title":"Mar Drugs"},{"key":"11402_CR159","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1093\/bioinformatics\/btx134","volume":"33","author":"KS Yarygin","year":"2017","unstructured":"Yarygin KS, Kovarsky BA, Bibikova TS et al (2017) Resistomap-online visualization of human gut microbiota antibiotic resistome. Bioinformatics 33:2205\u20132206. https:\/\/doi.org\/10.1093\/bioinformatics\/btx134","journal-title":"Bioinformatics"},{"key":"11402_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/database\/baw165","volume":"2017","author":"JC Wallace","year":"2017","unstructured":"Wallace JC, Port JA, Smith MN, Faustman EM (2017) FARME db: a functional antibiotic resistance element database. Database 2017:1\u20137. https:\/\/doi.org\/10.1093\/database\/baw165","journal-title":"Database"},{"key":"11402_CR161","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02752-21","author":"S Telhig","year":"2022","unstructured":"Telhig S, Ben Said L, Torres C et al (2022) Evaluating the potential and synergetic effects of microcins against multidrug-resistant enterobacteriaceae. Microbiol Spectr. https:\/\/doi.org\/10.1128\/spectrum.02752-21","journal-title":"Microbiol Spectr"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11402-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:58:57Z","timestamp":1769068737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11402-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":161,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11402"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11402-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships, which may be considered as potential competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No human or animal experiments were performed by the authors for this review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All the authors who are part of this manuscript have given their approval to the final version of this manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}}],"article-number":"318"}}